Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.59 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4425167 | 0.99 | GSK3B (0.59) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL23780643 | 0.83 | GSK3B (0.60) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Hydrochloric Acid SCHEMBL18813497 | 0.82 | GSK3B (0.59) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL5076231 | 0.79 | GSK3B (0.38) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL5091372 | 0.77 | GSK3B (0.81) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL29381876 | 0.75 | GSK3B (1.00) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL29357223 | 0.75 | GSK3B (1.00) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL4391839 | 0.75 | GSK3B (1.00) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL29402871 | 0.74 | GSK3B (1.00) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL29408793 | 0.74 | GSK3B (1.00) | GSK3BCDK1GSK3ACCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465610-B1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | EP | claimed |
| EP-1465610-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-13 | — | — | EP | claimed |
| WO-2003057202-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | WO | claimed |
| US-7476676-B2 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3β | ROCHE PALO ALTO LLC (US) | 2009-01-13 | — | — | US | disclosed |
| EP-1465610-B1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | HOFFMANN LA ROCHE (CH) | 2008-12-31 | — | — | EP | disclosed |
| EP-1465610-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20030176484-A1 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta | SYNTEX (U.S.A.) LLC | 2003-09-18 | — | — | US | disclosed |
| WO-2003057202-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176484-A1 | Methods for increasing bone formation using inhibitors of glycogen synthase kinase-3 betta | GSK3B, GSK3A, PHKA1 | GSK3B 1/4885CDK1 98/4885GSK3A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.